Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jeffrey L. Saver
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Suspected stroke identified by the Los Angeles Prehospital Stroke Screen

• Age 40-95, inclusive

• Last known well time within 2 hours of treatment initiation

• Deficit present for >/= 15 minutes

Exclusion Criteria:

• Coma

• Rapidly improving neurologic deficit

• Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound the neurological or functional outcome evaluations

• Systolic Blood Pressure (SBP) < 90 or > 220

• Known severe renal dysfunction (on dialysis or known chronic creatinine > 3.0)

• Severe respiratory distress (O2 sat < 90% or respiratory rate < 12 or >/= 24)

• Known second or third degree heart block with no pacemaker in place

• Major head trauma in the last 24 hours

• Recent stroke within prior 30 days

• Patient unable to give informed consent and no available on scene consent or assent provider